Generic placeholder image

Applied Drug Research, Clinical Trials and Regulatory Affairs

Editor-in-Chief

ISSN (Print): 2667-3371
ISSN (Online): 2667-338X

Mini-Review Article

Steering through Regulatory Currents: The Journey of India’s Pharma Industry with the USFDA

Author(s): Raj Kamal, Diksha, Priyanka Paul and Ankit Awasthi*

Volume 10, 2024

Published on: 19 September, 2024

Article ID: e26673371310378 Pages: 9

DOI: 10.2174/0126673371310378240808054710

Price: $65

TIMBC 2025
Abstract

Introduction and Objective: India's pharmaceutical industry faces challenges in meeting USFDA quality standards, impacting exports and reputation. This review examines the causes of non-compliance and proposes strategies to enhance compliance, predicting future trends.

Methods: This study conducts an analysis of USFDA warning letters to Indian manufacturers, an assessment of non-compliance issues, and an exploration of technological advancements in compliance, such as automation and AI.

Results: The study reveals a rise in non-compliance incidents, emphasizing the need for a robust quality culture, updated regulatory knowledge, and implementation of advanced technologies to improve compliance.

Conclusion: To maintain global competitiveness, India's pharma industry must adopt comprehensive strategies, leverage technology, and prepare proactively for regulatory changes. Future compliance will rely on remote auditing and real-time monitoring.

Keywords: USFDA, non-compliance, warning letters, cGMP, automation, AI.

[1]
Hoppe AP, Scribner CL. Unique and unprecedented compliance challenges in the biologics arena compliance handbook for pharmaceuticals, medical devices, and biologics. CRC Press 2003; pp. 542-75.
[2]
Rathore AS, Li Y, Chhabra H, Lohiya A. A retrospective analysis of letters issued to pharmaceutical companies from 2010–2020 J Pharmaceu Innova 2023; 18(2): 665-74.
[3]
Alsaidalani R, Elmadhoun B. Quality risk management in pharmaceutical manufacturing operations: case study for sterile product filling and final product handling stage. Sustainability (Basel) 2022; 14(15): 9618.
[http://dx.doi.org/10.3390/su14159618]
[5]
Jalundhwala F, Londhe V. A systematic review on implementing operational excellence as a strategy to ensure regulatory compliance: a roadmap for Indian pharmaceutical industry. Int J Lean Six Sigma 2023; 14(4): 730-58.
[http://dx.doi.org/10.1108/IJLSS-04-2022-0078]
[6]
Sahay A, Joshi VM. Dealing with the Coronavirus: The Case of the Indian Pharma Industry. Indian Institute of Management Ahmedabad 2023; pp. 1-46.
[7]
Dhiman SK, Gummadi V, Dureja H. Their potential to reduce the challenges that confront regulators and pharmaceutical industry. Appl Clinic Resear Clinic Tri Regula Affairs 2019; 6(1): 7-17.
[8]
Shaw B, Whitney P. Ethics and compliance in global pharmaceutical industry marketing and promotion: The role of the IFPMA and self-regulation. Pharmaceuticals Policy and Law 2016; 18(1-4): 199-206.
[http://dx.doi.org/10.3233/PPL-160443]
[9]
Botasheva LH, Dobrynina AK, Konovalova OV. Anti-corruption compliance designing in pharmaceutical companies.industry competitiveness: digitalization, management, and integration; 2021 2021. Cham: Springer International Publishing 2021; pp. 933-40.
[10]
Chisholm O, Critchley H. Future directions in regulatory affairs. Front Med (Lausanne) 2023; 9: 1082384.
[http://dx.doi.org/10.3389/fmed.2022.1082384] [PMID: 36698838]
[11]
Overgaard SM, Graham MG, Brereton T, Pencina MJ, Halamka JD, Vidal DE. Implementing quality management systems to close the AI translation gap and facilitate safe, ethical, and effective health AI solutions. npj Digi Med 2023; 6(1): 218.
[12]
Ispas L, Mironeasa C, Silvestri A. Risk-based approach in the implementation of integrated management systems: a systematic literature review. Sustainability (Basel) 2023; 15(13): 10251.
[http://dx.doi.org/10.3390/su151310251]
[13]
Wedha BY, Hindarto D. Maximizing erp benefits with enterprise architecture: a holistic approach. J Comp Net Archi High Perform Comp 2023; 5(2): 703-13.
[14]
Aziz LA-R, Andriansyah Y. The role artificial intelligence in modern banking: an exploration of ai-driven approaches for enhanced fraud prevention, risk management, and regulatory compliance. Rev Contemp Bus Analyt 2023; 6(1): 110-32.
[15]
Leno V, Polyvyanyy A, Dumas M, La Rosa M, Maggi FM. Robotic Process Mining: Vision and Challenges. Bus Inf Syst Eng 2021; 63(3): 301-14.
[16]
Akkari A, Valamede L. A new holistic approach for the integration of lean manufacturing tools and digital technologies. Int J Math Eng Manag Sci 2020; 5: 851-68.
[17]
Amuah J. Overcoming corporate disaster by leveraging the proactive power of enterprise risk management. SSRN 2023.
[http://dx.doi.org/10.2139/ssrn.4624088]
[18]
Arafa A, Sheerah HA, Alsalamah S. Emerging digital technologies in healthcare with a spotlight on cybersecurity: a narrative review. Information (Basel) 2023; 14(12): 640.
[http://dx.doi.org/10.3390/info14120640]
[19]
Kunduru AR. Cloud bpm application (appian) robotic process automation capabilities. Asian J Resear Comp Sci 2023; 16(3): 267-50.
[20]
JdA Dornelles, NF Ayala, AG Frank. How digital technologies enhance manufacturing workers’ activities. Comp Indus Eng 2022; 163: 107804.
[21]
Azamfirei V, Psarommatis F, Lagrosen Y. Application of automation for in-line quality inspection, a zero-defect manufacturing approach. J Manufac Sys 2023; 67: 1-22.
[http://dx.doi.org/10.1016/j.jmsy.2022.12.010]
[22]
Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics 2023; 15(7): 1916.
[http://dx.doi.org/10.3390/pharmaceutics15071916] [PMID: 37514102]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy